SCHEMBL6784725

SCHEMBL6784725

COC(=O)c1ccccc1NC(=O)/C=C(/C)c1nccc2ccccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 1/20 0.48
MAPK9 P45984 1/20 0.48
MAPK10 P53779 1/20 0.48
LMNA P02545 3/20 0.48
HTT P42858 2/20 0.48
HPGD P15428 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
KDM4E B2RXH2 7/20 0.47
ALDH1A1 P00352 4/20 0.47
KMT2A Q03164 4/20 0.47
MEN1 O00255 2/20 0.47
MAPT P10636 2/20 0.47
ALOX12 P18054 1/20 0.47
TERT O14746 2/20 0.45
GLA P06280 1/20 0.45
THRB P10828 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
POLB P06746 3/20 0.44
ATM Q13315 1/20 0.44
HSD17B10 Q99714 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6784904 0.89 TERT (0.58) LMNAHPGDSMN1; SMN2KDM4EALDH1A1
SCHEMBL6784252 0.79 ALDH1A1 (0.49) MAPK8MAPK9MAPK10LMNAHTT
SCHEMBL7240960 0.75 TERT (0.58) LMNAHTTHPGDSMN1; SMN2KDM4E
SCHEMBL3071834 0.75 LMNA (0.74) LMNAHTTHPGDSMN1; SMN2KDM4E
SCHEMBL7631322 0.75 CNR2 (0.52) SMN1; SMN2KDM4EKMT2AMEN1MAPT
SCHEMBL30301713 0.75 CNR2 (0.52) SMN1; SMN2KDM4EKMT2AMEN1MAPT
SCHEMBL6784219 0.74 TERT (0.78) LMNAHTTHPGDSMN1; SMN2KDM4E
SCHEMBL6791361 0.72 LMNA (0.49) LMNAHTTHPGDSMN1; SMN2KDM4E
SCHEMBL6783383 0.72 LTB4R (0.62) MAPK10LMNAHTTHPGDSMN1; SMN2
SCHEMBL6782877 0.72 HPGD (0.54) MAPK10LMNAHTTHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 MAPK8 2705/4885MAPK9 979/4885MAPK10 795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.